ALTERATIONS OF XANTHINE OXIDOREDUCTASE ACTIVITY IN RED BLOOD CELLS AFTER GLUCOCORTICOID TREATMENT IN RHEUMATOID ARTHRITIS

E. Mozgovaya1, S. Bedina1, A. Tofomjenko1, M. Mamus2, S. Spitsina2, I. Zborovskaya1
1Research Institute of Clinical and Experimental Rheumatology named after A.B. Zborovsky, Clinical Biochemistry Lab, Volgograd, Russian Federation

Background: According to modern concepts, rheumatoid arthritis (RA) refers to severe autoimmune rheumatic diseases. The activation of free radical oxidation processes is essential in the development of this disease [1]. Xanthine oxidoreductase is a significant reactive oxygen species source [2]. Despite the great advances in the treatment of rheumatoid arthritis (RA) associated with the introduction of innovative drugs and especially the improvement of the strategy for their use in clinical practice, glucocorticoids still remain an important component of RA pharmacotherapy in actual clinical practice.

Objectives: to evaluate the changes in activities of xanthine oxidoreductase interconvertible forms (xanthine oxidase, EC 1.17.3.2 and xanthine dehydrogenase, EC 1.17.1.4) in lysed red blood cells of RA patients in relation with glucocorticoid treatment.

Methods: 47 RA patients with verified RA and 30 healthy controls were enrolled in the study. The diagnosis was verified using the 2010 ACR/EULAR criteria 2010. All patients have moderate DAS28 scores. RA patients were randomized into 2 groups comparable in gender, age and the principal clinical manifestations. Methylprednisolone (Metipred, Orion Corp.), average dose 30 mg/d, was administered intramuscularly in the respective groups. Xanthine oxidase (XO) and xanthine dehydrogenase (XDH) activities were measured in lysed red blood cells by spectrophotometric method as previously described [3]. The changes of these enzymes activities were studied in RA patients before and after the injection of glucocorticoids. Statistical comparison tests were selected in according to common guidelines, differences were considered significant when p<0.05. Central tendencies were expressed as means±SEM.

Results: Mean age of patients in methylprednisolone group was 41.8±1.05 years, and mean RA duration (± SEM) was 7.9±0.21 years. Mean age of patients in dипроspan group was 40.9±1.07 years, and mean RA duration was 8.0±0.33 years. Significant decrease of XO activity and increase of XDH activity were observed in lysed red blood cells of RA patients just after the injection of each glucocorticoid drug. Changes of the enzymatic activities in lysed red blood cells were more pronounced in methylprednisolone group. However enzymatic activity did not reach the level of healthy controls. As described previously, decreased XO activity and increased XDH activity were observed in plasma of RA patients just after the injection of the average therapeutic doses of glucocorticoids, as well as in lysed lymphocytes just after the injection of methylprednisolone [4].

Conclusion: Treatment with methylprednisolone and betamethasone can affect the balance of XO/XDH activity and increase the antioxidant potential of the blood. This effect can exert beneficial influence on autoimmune inflammation in RA.

REFERENCES:

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2021-eular.3168

AB0082

TIME COURSE OF INTESTINAL PERMEABILITY AND BACTERIAL TRANSLLOCATION IN THE MODEL OF ADJUVANT-INDUCED ARTHRITIS

S. Heucet1, P. Totoson2, H. Martin2, C. Peyronne1, M. Tournier1, P. Saas2, J. P. Pais-De-Barros4, D. Wending1, C. Demougéot2, F. Verhoeven1, L. Šenolt2,3.
1Centre hospitalier régional universitaire de Besançon, Rheumatology, Besançon, France; 2EA4267 PEPIPE LAB, Physiology, Besançon, France; 3UMR 1098, Interactions Hôte Greffe Tumeur, Besançon, France; 4UMR 1231, Plateforme de lipidomique, Dijon, France

Background: Intestinal inflammation, dysbiosis, intestinal permeability (IP) and bacterial translocation (BT) have been identified in patients with spondyloarthritis but the time at which they appear and their contribution to the pathogenesis of the disease is still a matter of debate.

Objectives: To investigate the time-course of intestinal inflammation, IP and BT in a rat model of reactive arthritis, a subgroup of SpA, the adjuvant-induced arthritis model.

Methods: Adjuvant-induced arthritis (AIA) was induced in 6-week-old male Lewis rats by an injection at the base of the tail of Mycobacterium butyricum with incomplete Freund’s adjuvant (Day (D) 0). Control rats received saline using the same procedure. Body weights and a clinical arthritis score were daily assessed. A group of AIA and control rats (n=15 per group) were euthanized at different times of arthritis: D4 for the pre-arthritic phase (AIA-preclinical), D11 for the onset of arthritis (AIA-onset) and D28 for the acute phase (AIA-acute). In each group (AIA and control, n=15 per group), IP was assessed by measuring plasma levels of zonulin (ELISA) and ileal mRNA expression of zonulin and occludin (RT-qPCR), BT was studied by measuring bacterial endotoxins (or LPS, by LCMS2 method), soluble CD-14 (sCD14, ELISA) and ileal mRNA expression of TLR-4, and intestinal inflammation was assessed by measuring ileal mRNA expression of IL-8, IL-33, IL-17, IL-23p19 and TNF-α (RT-qPCR). Joint damage was assessed by the determination of a clinical and radiographic score of hind paws.

Results: Body weights of AIA rats decreased from D4 to D28 as compared to controls, in parallel to the development of a severe clinical and radiographic arthritis disease from D11 and D28. Compared to control rats, AIA induced an increase in plasma zonulin levels at D4, D11 but not at D28. Ileal mRNA zonulin overexpression occurred at D11 while occludin was unchanged. As early as Day 4 (preclinical phase), mRNA of IL-8, IL-33 and IL-17 were overexpressed in ileum from AIA. At Day 11 (onset), overexpression of IL-8 persisted and mRNA expression of TNF-α and IL-23p19 increased in AIA. Neither LPS levels nor ileal mRNA expression of TLR-4 were changed by arthritis whatever the phase of arthritis. By contrast, blood levels of sCD-14 was significantly increased in the AIA group at all stages of arthritis. No correlation was found between clinical and radiographic arthritis scores and zonulin or LPS levels. Conversely, a negative correlation was observed between intestinal IL-6 mRNA expression and arthritis stage (r=-0.3, p=0.02).

Conclusion: In an animal model of SpA, intestinal inflammation and increased intestinal permeability occur prior to joint inflammation, suggesting a role of these disorders in the pathogenesis of this disease.

Acknowledgements: I would like to thank the Société Française de Rhumatologie for its support in this work.

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2021-eular.3207

AB0061

DIFFICULT-TO-TREAT RHEUMATOID ARTHRITIS: A BIOMARKER SCREENING PILOT STUDY

J. Baloun1, A. Pekacova2,3, H. Mann1,2, J. Vencovsky1,2, K. Pøvelka1,2, L. Senolt1,3, 1Institute of Rheumatology, Department of Rheumatology, Prague, Czech Republic; 21st Faculty of Medicine, Charles University, Department of Rheumatology, Prague, Czech Republic; 3Institute of Rheumatology, Department of Experimental Rheumatology, Prague, Czech Republic

Background: Despite modern therapeutic approaches, many patients with rheumatoid arthritis (RA) remain symptomatic after several cycles of treatment and may become so called Difficult-To-Treat (D2T). D2T RA is a multifactorial condition in which different factors may be major determinants of the persistence of signs and symptoms, which is seldom caused by drug resistance only. Discovering new biomarkers is necessary to develop tailored therapies that will be effective in an individual patient at each stage of the disease.

Objectives: The primary aim of this pilot study was to validate a target proteomic technique for the proteome profiling of the two cohorts of RA patients and controls. Moreover, we searched for potential plasma biomarker(s) predicting D2T RA.

Methods: Seven RA patients with persistent remission on biological therapy in two consecutive examinations 12 wks apart (mean age 59.6±14 yrs), seven D2T RA patients fulfilling proposed EULAR definition of D2T RA1 (mean age 59.3±13 yrs), and six healthy controls (mean age 58.8±15 yrs) were included in this study. All subjects were females and their samples were collected before starting biological therapy. We employed plasma samples from Offi carcinomas with nano-flow UPLC Dionex Ultimate 3000. Prior to quantification, 125 plasma proteins were modified by PepTiquant Plus Human kit to increase the sensitivity. Data were analysed by ANOVA and Tukey’s posthoc test with false-detection-rate adjustment.

Results: The target proteome profiling reliably quantified 92 from 125 labelled proteins. Our follow-up statistical analysis revealed ten plasma proteins, which significantly differed among study groups. Notably, we found significantly different plasma levels of paraoxonase/arylesterase 1 (PON1), an esterase with an antioxidant characteristic preventing lipid peroxidation2, between RA patients and controls and between RA patients with persistent remission and D2T RA patients.